Peptide Receptor Radionuclide Therapy in Thyroid Cancer

The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited. While there are several systemic targeted therapies, such as tyrosine kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubbi, Sriram, Koch, Christian A., Klubo-Gwiezdzinska, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197113/
https://www.ncbi.nlm.nih.gov/pubmed/35712243
http://dx.doi.org/10.3389/fendo.2022.896287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197113/
https://www.ncbi.nlm.nih.gov/pubmed/35712243
http://dx.doi.org/10.3389/fendo.2022.896287

Ejemplares similares